Main Results

By the end of the grant period, we expect to have established:

  • A robust genetic risk profile: validated and implemented
  • Genetic risk testing (based on SNPs and family history): as a supplement/alternative to PSA testing in a general medical practice setting, and as an alternative to continued surveillance of men with steadily elevated PSA and repeated negative biopsies
  • A PC prevention clinic: for follow-up of high-risk individuals, including surveillance of the psychological impact of being part of a high-risk group/family and subjected to repeated testing
  • A set of new biomarkers that can discriminate between aggressive and non-aggressive PC, and completed validation of these in international collaborations
  • Algorithms and nomograms that enable prediction of aggressiveness, based on multiple parameters, validated and implemented in daily routines as a clinical prospective study
  • A software tool for systems biology analysis of the full range of NGS data, including a highly specialized cancer research and diagnostics module to be sold and marketed worldwide
  • Knowledge sharing and -transfer between international experts in prostate cancer in USA, Germany and China by training and interchange of PhD students and post docs
  • An improved cost-effectiveness ratio in the treatment of PC in Denmark, without worsening but rather improving the clinical outcome


To pave the way for inclusion of our findings in routine treatment of PC patients in Europe we will be in close contact with the EORTC (European Organisation for Research and Treatment of Cancer), which acts as a body for recommendation of routine procedures.